Want to see MPLT full AI Analyst Report?

MapLight Therapeutics, Inc. (MPLT) Stock Forecast & Price Target

36 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MPLT Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

MapLight

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MPLT Stock 12 Month Forecast

Average Price Target

$26.00

▲(88.82% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for MapLight Therapeutics, Inc. in the last 3 months. The average price target is $26.00 with a high forecast of $43.00 and a low forecast of $13.00. The average price target represents a 88.82% change from the last price of $13.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","20":"$20","28":"$28","36":"$36","44":"$44"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$43.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,20,28,36,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.31,15.593846153846155,17.877692307692307,20.161538461538463,22.445384615384615,24.729230769230767,27.013076923076923,29.296923076923076,31.580769230769228,33.864615384615384,36.14846153846154,38.43230769230769,40.716153846153844,{"y":43,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.31,14.286153846153846,15.262307692307694,16.23846153846154,17.214615384615385,18.19076923076923,19.166923076923077,20.143076923076926,21.119230769230768,22.095384615384617,23.07153846153846,24.04769230769231,25.023846153846154,{"y":26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.31,13.286153846153846,13.262307692307692,13.23846153846154,13.214615384615385,13.19076923076923,13.166923076923077,13.143076923076924,13.11923076923077,13.095384615384615,13.071538461538461,13.047692307692309,13.023846153846154,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.34,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.565,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.93,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.83,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$43.00

Average Price Target$26.00

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

$45→$43

Buy

212.27%

Upside

Assigned

08/31/26

MapLight Therapeutics price target lowered to $43 from $45 at NeedhamMapLight Therapeutics price target lowered to $43 from $45 at Needham

Sean Laaman

Morgan Stanley

$21

Hold

52.51%

Upside

Assigned

08/17/26

Morgan Stanley Keeps Their Hold Rating on MapLight Therapeutics, Inc. (MPLT)

Francois Brisebois

LifeSci Capital

$37

Buy

168.70%

Upside

Reiterated

08/14/26

Analysts' Top NA Picks: Solv Energy (MWH), MapLight Therapeutics, Inc. (MPLT)

Evan Seigerman

BMO Capital

$46→$20

Buy

45.24%

Upside

Reiterated

08/13/26

Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (NASDAQ: CAMP), MapLight Therapeutics, Inc. (NASDAQ: MPLT) and Andersen Group, Inc. Class A (NYSE: ANDG)

Ashwani Verma

UBS

$52→$13

Hold

-5.59%

Downside

Downgraded

08/11/26

MapLight Therapeutics downgraded to Neutral from Buy at UBSMapLight Therapeutics downgraded to Neutral from Buy at UBS

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$25

Buy

81.55%

Upside

Reiterated

07/30/26

MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies

Ram Selvaraju

H.C. Wainwright

$45→$26

Buy

88.82%

Upside

Reiterated

07/28/26

MapLight Therapeutics price target lowered to $26 from $45 at H.C. WainwrightMapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright

Adam Vogel

Craig-Hallum

$40→$25

Buy

81.55%

Upside

Reiterated

07/28/26

MapLight Therapeutics price target lowered to $25 from $40 at Craig-HallumMapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum

Sumant Kulkarni

Canaccord Genuity

$43→$24

Buy

74.29%

Upside

Reiterated

07/27/26

MapLight Therapeutics price target raised to $43 from $35 at CanaccordMapLight Therapeutics price target raised to $43 from $35 at Canaccord

Tiago Fauth

Raymond James

$46

Buy

234.06%

Upside

Initiated

06/25/26

MapLight Therapeutics initiated with a Strong Buy at Raymond JamesMapLight Therapeutics initiated with a Strong Buy at Raymond James

Paul Matteis

Stifel Nicolaus

$28→$36

Buy

161.44%

Upside

Reiterated

06/02/26

MapLight Therapeutics price target raised to $36 from $28 at StifelMapLight Therapeutics price target raised to $36 from $28 at Stifel

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

05/14/26

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), MapLight Therapeutics, Inc. (MPLT)

Marc Goodman

Leerink Partners

$30

Buy

117.86%

Upside

Initiated

11/21/25

MapLight Therapeutics initiated with an Outperform at LeerinkMapLight Therapeutics initiated with an Outperform at Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

$45→$43

Buy

212.27%

Upside

Assigned

08/31/26

MapLight Therapeutics price target lowered to $43 from $45 at NeedhamMapLight Therapeutics price target lowered to $43 from $45 at Needham

Sean Laaman

Morgan Stanley

$21

Hold

52.51%

Upside

Assigned

08/17/26

Morgan Stanley Keeps Their Hold Rating on MapLight Therapeutics, Inc. (MPLT)

Francois Brisebois

LifeSci Capital

$37

Buy

168.70%

Upside

Reiterated

08/14/26

Analysts' Top NA Picks: Solv Energy (MWH), MapLight Therapeutics, Inc. (MPLT)

Evan Seigerman

BMO Capital

$46→$20

Buy

45.24%

Upside

Reiterated

08/13/26

Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (NASDAQ: CAMP), MapLight Therapeutics, Inc. (NASDAQ: MPLT) and Andersen Group, Inc. Class A (NYSE: ANDG)

Ashwani Verma

UBS

$52→$13

Hold

-5.59%

Downside

Downgraded

08/11/26

MapLight Therapeutics downgraded to Neutral from Buy at UBSMapLight Therapeutics downgraded to Neutral from Buy at UBS

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$25

Buy

81.55%

Upside

Reiterated

07/30/26

MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies

Ram Selvaraju

H.C. Wainwright

$45→$26

Buy

88.82%

Upside

Reiterated

07/28/26

MapLight Therapeutics price target lowered to $26 from $45 at H.C. WainwrightMapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright

Adam Vogel

Craig-Hallum

$40→$25

Buy

81.55%

Upside

Reiterated

07/28/26

MapLight Therapeutics price target lowered to $25 from $40 at Craig-HallumMapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum

Sumant Kulkarni

Canaccord Genuity

$43→$24

Buy

74.29%

Upside

Reiterated

07/27/26

MapLight Therapeutics price target raised to $43 from $35 at CanaccordMapLight Therapeutics price target raised to $43 from $35 at Canaccord

Tiago Fauth

Raymond James

$46

Buy

234.06%

Upside

Initiated

06/25/26

MapLight Therapeutics initiated with a Strong Buy at Raymond JamesMapLight Therapeutics initiated with a Strong Buy at Raymond James

Paul Matteis

Stifel Nicolaus

$28→$36

Buy

161.44%

Upside

Reiterated

06/02/26

MapLight Therapeutics price target raised to $36 from $28 at StifelMapLight Therapeutics price target raised to $36 from $28 at Stifel

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

05/14/26

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), MapLight Therapeutics, Inc. (MPLT)

Marc Goodman

Leerink Partners

$30

Buy

117.86%

Upside

Initiated

11/21/25

MapLight Therapeutics initiated with an Outperform at LeerinkMapLight Therapeutics initiated with an Outperform at Leerink

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MapLight Therapeutics, Inc.

3 Months

Sumant KulkarniCanaccord Genuity

Success Rate

2/3 ratings generated profit

Average Return

+5.20%

Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.20% per trade.

1 Year

Sumant KulkarniCanaccord Genuity

Success Rate

1/3 ratings generated profit

Average Return

-29.87%

Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -29.87% per trade.

2 Years

Sumant KulkarniCanaccord Genuity

Success Rate

1/3 ratings generated profit

Average Return

-29.87%

Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -29.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MPLT Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MPLT has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MPLT average Analyst price target in the past 3 months is 26.00.

Each month's total comprises the sum of three months' worth of ratings.

MPLT Financial Forecast

MPLT Earnings Forecast

Next quarter’s earnings estimate for MPLT is -$1.35 with a range of -$1.45 to -$1.00. The previous quarter’s EPS was -$1.34. MPLT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year MPLT has its overall industry.

No data currently available

MPLT Sales Forecast

Next quarter’s sales forecast for MPLT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MPLT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year MPLT has its overall industry.

MPLT Stock Forecast FAQ

What is MPLT’s average 12-month price target, according to analysts?

Based on analyst ratings, MapLight Therapeutics, Inc.’s 12-month average price target is 26.00.

What is MPLT’s upside potential, based on the analysts’ average price target?

MapLight Therapeutics, Inc. has 88.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MPLT a Buy, Sell or Hold?

MapLight Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is MapLight Therapeutics, Inc.’s price target?

The average price target for MapLight Therapeutics, Inc. is 26.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $43.00 ,the lowest forecast is $13.00. The average price target represents 88.82% Increase from the current price of $13.77.

What do analysts say about MapLight Therapeutics, Inc.?

MapLight Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of MPLT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

MapLight Therapeutics, Inc. (MPLT) Stock Forecast & Price Target

MPLT Analyst Ratings

MPLT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MapLight Therapeutics, Inc.

MPLT Analyst Recommendation Trends

MPLT Financial Forecast

MPLT Earnings Forecast

MPLT Sales Forecast

MPLT Stock Forecast FAQ

Detailed List of Analyst Forecasts